NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

AIM ImmunoTech Inc. (AIM) Stock Analysis

AIM ImmunoTech Inc. (AIM) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

AIM

$0.23

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AIM with… →

AIM Key Statistics

As of Sep 4, 2026
Trading
Open
$0.23
Previous Close
$0.23
Day's Range
0.23–0.24
52-Week Range
0.19–2.89
Volume
8.54M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
Market Cap
$6.93M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.71
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
72.93
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.71
Financials (FY)
Revenue (FY)
$88.00K−48.24%
Net Income (FY)
−$13.96M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
30.44M
1-Year Return
−90.28%
Dividend and dates
Avg Volume
6.16M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AIM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−79.01%
2025−94.35%
2024−54.55%
2023+41.94%
2022−66.30%
2021−48.60%
2020+231.48%
2019−93.18%
2018−48.57%
2017−49.28%
2016 (partial year)−68.06%

As of September 4, 2026.

AIM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$88.00K−$13.96M−15861.4%
2024$170.00K−$17.32M−10188.2%
2023$202.00K−$28.96M−14337.6%
2022$141.00K−$19.45M−13790.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$88.00K−$40.00K−$11.66M−$13.96M−15861.4%
2024$170.00K$139.00K−$19.77M−$17.32M−10188.2%
2023$202.00K$160.00K−$31.92M−$28.96M−14337.6%
2022$141.00K$141.00K−$19.92M−$19.45M−13790.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AIM Valuation vs Biotechnology Median

Median of 656 stocks
MetricAIMBiotechnology medianvs median
P/S ratio72.9315.264.8x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

AIM ImmunoTech Inc. (AIM) is capitalised at $6.93M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 19 employees.

The 52-week range on file runs from $0.19 to $2.89. The most recent close on file for AIM is $0.23, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 21.05% above that 52-week low.

Financial Health

In fiscal 2025, AIM ImmunoTech Inc. reported revenue of $88.00K. Against the prior fiscal year total of $170.00K, that is a change of −48.24%. The same year closed with a net loss of $13.96M. Profit margin runs at 0%. Trailing earnings per share are −0.71.

Across the 4 fiscal years on file, revenue moves from $141.00K in 2022 to $88.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.71. Measured against sales, the shares trade at 72.93 times revenue. On price-to-sales that is 4.8 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.19. Annualized volatility over the trailing 10 years is 133.55%. Over the trailing twelve months the price has returned −90.28%. Measured over 10 years, that is −63.87% a year compounded.

Growth & Income

No dividend is on file for AIM.

Across the complete calendar years on file, 2020 returned +231.48% and 2025 returned −94.35%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −79.01% year to date.

Peer Comparison

AIM ImmunoTech Inc. (AIM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AIM ImmunoTech Inc. AIM $6.93M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. AIM ImmunoTech Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Visit website →